List of high-quality authors
Oak Technology: It is planned to use no more than 300 million yuan of its own idle funds to purchase short-term bank wealth management products
Oak Technology announced that the company and its subsidiaries intend to use their own idle funds of up to 300 million yuan to purchase short-term bank wealth management products, which will be valid for one year from the date of approval by the board of directors, and the amount can be used on a rolling basis during the authorization period.
Chongqing Three Gorges: 2023 annual loss of 30 million yuan and 40 million yuan].
Chongqing Three Gorges announced its 2023 annual performance forecast, with a net profit loss attributable to shareholders of listed companies of 30 million yuan and 40 million yuan in the reporting period, and a profit of 5244 yuan in the same period last year540,000 yuan.
GCL Integration: Net profit in 2023 is expected to increase by 152 year-on-year87%-270.88%】
GCL Integration released a performance forecast, and it is expected that the net profit attributable to the parent company in 2023 will be 1500 million yuan-2200 million yuan, a year-on-year increase of 15287%-270.88%。During the reporting period, the main reasons for the company's performance growth were as follows: module business shipments ranked among the top in the industry, production and sales were booming, and profitability increased significantly. Other businesses go hand in hand to contribute new profit growth points.
Baosteel's performance report: net profit of 12 billion yuan in 2023 will decrease by 1% year-on-year48%】
Baosteel Co., Ltd. released a performance report, with a net profit of 12 billion yuan in 2023, a year-on-year decrease of 148%。
Sinopharm Modern: The holding company obtained a veterinary drug business license
Sinopharm Modern announced that the holding company Qinghai Biopharmaceutical Factory *** hereinafter referred to as Sinopharm Qinghai Biologics) received the "Veterinary Drug Business License" issued by the Qinghai Provincial Department of Agriculture and Rural Affairs. Sinopharm Qinghai Biotech is a professional enterprise in the production of veterinary biological products and biotoxins, with an operating income of 4,900 in 202210,000 yuan, net profit 811$950,000 (audited).